These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38865484)

  • 1. Nutrient-sensitizing drug repurposing screen identifies lomerizine as a mitochondrial metabolism inhibitor of chronic myeloid leukemia.
    Khalaf A; de Beauchamp L; Kalkman E; Rattigan K; Himonas E; Jones J; James D; Shokry ESA; Scott MT; Dunn K; Tardito S; Copland M; Sumpton D; Shanks E; Helgason GV
    Sci Transl Med; 2024 Jun; 16(751):eadi5336. PubMed ID: 38865484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.
    Kuntz EM; Baquero P; Michie AM; Dunn K; Tardito S; Holyoake TL; Helgason GV; Gottlieb E
    Nat Med; 2017 Oct; 23(10):1234-1240. PubMed ID: 28920959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
    Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
    Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
    Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
    Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
    Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
    Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
    Zhou M; Zhang X; Liu C; Nie D; Li S; Lai P; Jin Y
    Oncogene; 2021 May; 40(20):3564-3577. PubMed ID: 33931742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
    Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
    Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
    Bellodi C; Lidonnici MR; Hamilton A; Helgason GV; Soliera AR; Ronchetti M; Galavotti S; Young KW; Selmi T; Yacobi R; Van Etten RA; Donato N; Hunter A; Dinsdale D; Tirrò E; Vigneri P; Nicotera P; Dyer MJ; Holyoake T; Salomoni P; Calabretta B
    J Clin Invest; 2009 May; 119(5):1109-23. PubMed ID: 19363292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
    Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T
    Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
    Jin Y; Zhou J; Xu F; Jin B; Cui L; Wang Y; Du X; Li J; Li P; Ren R; Pan J
    J Clin Invest; 2016 Oct; 126(10):3961-3980. PubMed ID: 27643437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
    Lin H; Chen M; Rothe K; Lorenzi MV; Woolfson A; Jiang X
    Oncotarget; 2014 Sep; 5(18):8637-50. PubMed ID: 25226617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
    Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
    J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors.
    Tanaka Y; Takeda R; Fukushima T; Mikami K; Tsuchiya S; Tamura M; Adachi K; Umemoto T; Asada S; Watanabe N; Morishita S; Imai M; Nagata M; Araki M; Takizawa H; Fukuyama T; Lamagna C; Masuda ES; Ito R; Goyama S; Komatsu N; Takaku T; Kitamura T
    Nat Commun; 2022 Jan; 13(1):271. PubMed ID: 35022428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
    Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
    Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
    Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
    Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
    Ma L; Shan Y; Bai R; Xue L; Eide CA; Ou J; Zhu LJ; Hutchinson L; Cerny J; Khoury HJ; Sheng Z; Druker BJ; Li S; Green MR
    Sci Transl Med; 2014 Sep; 6(252):252ra121. PubMed ID: 25186176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1.
    Li F; He B; Ma X; Yu S; Bhave RR; Lentz SR; Tan K; Guzman ML; Zhao C; Xue HH
    Cell Stem Cell; 2017 Sep; 21(3):359-373.e5. PubMed ID: 28844837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy and mitochondrial metabolism: insights into their role and therapeutic potential in chronic myeloid leukaemia.
    Baquero P; Dawson A; Helgason GV
    FEBS J; 2019 Apr; 286(7):1271-1283. PubMed ID: 30222247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells.
    Rattigan KM; Brabcova Z; Sarnello D; Zarou MM; Roy K; Kwan R; de Beauchamp L; Dawson A; Ianniciello A; Khalaf A; Kalkman ER; Scott MT; Dunn K; Sumpton D; Michie AM; Copland M; Tardito S; Gottlieb E; Vignir Helgason G
    Nat Commun; 2023 Aug; 14(1):4634. PubMed ID: 37591854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
    Prost S; Relouzat F; Spentchian M; Ouzegdouh Y; Saliba J; Massonnet G; Beressi JP; Verhoeyen E; Raggueneau V; Maneglier B; Castaigne S; Chomienne C; Chrétien S; Rousselot P; Leboulch P
    Nature; 2015 Sep; 525(7569):380-3. PubMed ID: 26331539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.